Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Buprenorphine-Maintained Adult Subjects
NCT01820442 is registered in ClinicalTrials.gov with USWM, LLC (dba US WorldMeds) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Buprenorphine-Maintained Adult Subjects
- Lead sponsor
- USWM, LLC (dba US WorldMeds)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2013
- Completion date
- September 30, 2013
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
buprenorphine withdrawal syndrome, opioid dependence